Cargando…
Design of polyaspartic acid peptide-poly (ethylene glycol)-poly (ε-caprolactone) nanoparticles as a carrier of hydrophobic drugs targeting cancer metastasized to bone
Treatment of cancer metastasized to bone is still a challenge due to hydrophobicity, instability, and lack of target specificity of anticancer drugs. Poly (ethylene glycol)-poly (ε-caprolactone) polymer (PEG-PCL) is an effective, biodegradable, and biocompatible hydrophobic drug carrier, but lacks b...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428813/ https://www.ncbi.nlm.nih.gov/pubmed/28507436 http://dx.doi.org/10.2147/IJN.S133787 |
_version_ | 1783235907879436288 |
---|---|
author | Liu, Jinsong Zeng, Youyun Shi, Shuai Xu, Lihua Zhang, Hualin Pathak, Janak L Pan, Yihuai |
author_facet | Liu, Jinsong Zeng, Youyun Shi, Shuai Xu, Lihua Zhang, Hualin Pathak, Janak L Pan, Yihuai |
author_sort | Liu, Jinsong |
collection | PubMed |
description | Treatment of cancer metastasized to bone is still a challenge due to hydrophobicity, instability, and lack of target specificity of anticancer drugs. Poly (ethylene glycol)-poly (ε-caprolactone) polymer (PEG-PCL) is an effective, biodegradable, and biocompatible hydrophobic drug carrier, but lacks bone specificity. Polyaspartic acid with eight peptide sequences, that is, (Asp)(8), has a strong affinity to bone surface. The aim of this study was to synthesize (Asp)(8)-PEG-PCL nanoparticles as a bone-specific carrier of hydrophobic drugs to treat cancer metastasized to bone. (1)H nuclear magnetic resonance, Fourier transform infrared spectroscopy, and transmission electron microscopy data showed that (Asp)(8)-PEG-PCL nanoparticles (size 100 nm) were synthesized successfully. (Asp)(8)-PEG-PCL nanoparticles did not promote erythrocyte aggregation. Fluorescence microscopy showed clear uptake of Nile red-loaded (Asp)(8)-PEG-PCL nanoparticles by cancer cells. (Asp)(8)-PEG-PCL nanoparticles did not show cytotoxic effect on MG63 and human umbilical vein endothelial cells at the concentration of 10–800 μg/mL. (Asp)(8)-PEG-PCL nanoparticles bound with hydroxyapatite 2-fold more than PEG-PCL. Intravenously injected (Asp)(8)-PEG-PCL nanoparticles accumulated 2.7-fold more on mice tibial bone, in comparison to PEG-PCL. Curcumin is a hydrophobic anticancer drug with bone anabolic properties. Curcumin was loaded in the (Asp)(8)-PEG-PCL. (Asp)(8)-PEG-PCL showed 11.07% loading capacity and 95.91% encapsulation efficiency of curcumin. The curcumin-loaded (Asp)(8)-PEG-PCL nanoparticles gave sustained release of curcumin in high dose for >8 days. The curcumin-loaded (Asp)(8)-PEG-PCL nanoparticles showed strong antitumorigenic effect on MG63, MCF7, and HeLa cancer cells. In conclusion, (Asp)(8)-PEG-PCL nanoparticles were biocompatible, permeable in cells, a potent carrier, and an efficient releaser of hydrophobic anticancer drug and were bone specific. The curcumin-loaded (Asp)(8)-PEG-PCL nanoparticles showed strong antitumorigenic ability in vitro. Therefore, (Asp)(8)-PEG-PCL nanoparticles could be a potent carrier of hydrophobic anticancer drugs to treat the cancer metastasized to bone. |
format | Online Article Text |
id | pubmed-5428813 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-54288132017-05-15 Design of polyaspartic acid peptide-poly (ethylene glycol)-poly (ε-caprolactone) nanoparticles as a carrier of hydrophobic drugs targeting cancer metastasized to bone Liu, Jinsong Zeng, Youyun Shi, Shuai Xu, Lihua Zhang, Hualin Pathak, Janak L Pan, Yihuai Int J Nanomedicine Original Research Treatment of cancer metastasized to bone is still a challenge due to hydrophobicity, instability, and lack of target specificity of anticancer drugs. Poly (ethylene glycol)-poly (ε-caprolactone) polymer (PEG-PCL) is an effective, biodegradable, and biocompatible hydrophobic drug carrier, but lacks bone specificity. Polyaspartic acid with eight peptide sequences, that is, (Asp)(8), has a strong affinity to bone surface. The aim of this study was to synthesize (Asp)(8)-PEG-PCL nanoparticles as a bone-specific carrier of hydrophobic drugs to treat cancer metastasized to bone. (1)H nuclear magnetic resonance, Fourier transform infrared spectroscopy, and transmission electron microscopy data showed that (Asp)(8)-PEG-PCL nanoparticles (size 100 nm) were synthesized successfully. (Asp)(8)-PEG-PCL nanoparticles did not promote erythrocyte aggregation. Fluorescence microscopy showed clear uptake of Nile red-loaded (Asp)(8)-PEG-PCL nanoparticles by cancer cells. (Asp)(8)-PEG-PCL nanoparticles did not show cytotoxic effect on MG63 and human umbilical vein endothelial cells at the concentration of 10–800 μg/mL. (Asp)(8)-PEG-PCL nanoparticles bound with hydroxyapatite 2-fold more than PEG-PCL. Intravenously injected (Asp)(8)-PEG-PCL nanoparticles accumulated 2.7-fold more on mice tibial bone, in comparison to PEG-PCL. Curcumin is a hydrophobic anticancer drug with bone anabolic properties. Curcumin was loaded in the (Asp)(8)-PEG-PCL. (Asp)(8)-PEG-PCL showed 11.07% loading capacity and 95.91% encapsulation efficiency of curcumin. The curcumin-loaded (Asp)(8)-PEG-PCL nanoparticles gave sustained release of curcumin in high dose for >8 days. The curcumin-loaded (Asp)(8)-PEG-PCL nanoparticles showed strong antitumorigenic effect on MG63, MCF7, and HeLa cancer cells. In conclusion, (Asp)(8)-PEG-PCL nanoparticles were biocompatible, permeable in cells, a potent carrier, and an efficient releaser of hydrophobic anticancer drug and were bone specific. The curcumin-loaded (Asp)(8)-PEG-PCL nanoparticles showed strong antitumorigenic ability in vitro. Therefore, (Asp)(8)-PEG-PCL nanoparticles could be a potent carrier of hydrophobic anticancer drugs to treat the cancer metastasized to bone. Dove Medical Press 2017-05-08 /pmc/articles/PMC5428813/ /pubmed/28507436 http://dx.doi.org/10.2147/IJN.S133787 Text en © 2017 Liu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Liu, Jinsong Zeng, Youyun Shi, Shuai Xu, Lihua Zhang, Hualin Pathak, Janak L Pan, Yihuai Design of polyaspartic acid peptide-poly (ethylene glycol)-poly (ε-caprolactone) nanoparticles as a carrier of hydrophobic drugs targeting cancer metastasized to bone |
title | Design of polyaspartic acid peptide-poly (ethylene glycol)-poly (ε-caprolactone) nanoparticles as a carrier of hydrophobic drugs targeting cancer metastasized to bone |
title_full | Design of polyaspartic acid peptide-poly (ethylene glycol)-poly (ε-caprolactone) nanoparticles as a carrier of hydrophobic drugs targeting cancer metastasized to bone |
title_fullStr | Design of polyaspartic acid peptide-poly (ethylene glycol)-poly (ε-caprolactone) nanoparticles as a carrier of hydrophobic drugs targeting cancer metastasized to bone |
title_full_unstemmed | Design of polyaspartic acid peptide-poly (ethylene glycol)-poly (ε-caprolactone) nanoparticles as a carrier of hydrophobic drugs targeting cancer metastasized to bone |
title_short | Design of polyaspartic acid peptide-poly (ethylene glycol)-poly (ε-caprolactone) nanoparticles as a carrier of hydrophobic drugs targeting cancer metastasized to bone |
title_sort | design of polyaspartic acid peptide-poly (ethylene glycol)-poly (ε-caprolactone) nanoparticles as a carrier of hydrophobic drugs targeting cancer metastasized to bone |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428813/ https://www.ncbi.nlm.nih.gov/pubmed/28507436 http://dx.doi.org/10.2147/IJN.S133787 |
work_keys_str_mv | AT liujinsong designofpolyasparticacidpeptidepolyethyleneglycolpolyecaprolactonenanoparticlesasacarrierofhydrophobicdrugstargetingcancermetastasizedtobone AT zengyouyun designofpolyasparticacidpeptidepolyethyleneglycolpolyecaprolactonenanoparticlesasacarrierofhydrophobicdrugstargetingcancermetastasizedtobone AT shishuai designofpolyasparticacidpeptidepolyethyleneglycolpolyecaprolactonenanoparticlesasacarrierofhydrophobicdrugstargetingcancermetastasizedtobone AT xulihua designofpolyasparticacidpeptidepolyethyleneglycolpolyecaprolactonenanoparticlesasacarrierofhydrophobicdrugstargetingcancermetastasizedtobone AT zhanghualin designofpolyasparticacidpeptidepolyethyleneglycolpolyecaprolactonenanoparticlesasacarrierofhydrophobicdrugstargetingcancermetastasizedtobone AT pathakjanakl designofpolyasparticacidpeptidepolyethyleneglycolpolyecaprolactonenanoparticlesasacarrierofhydrophobicdrugstargetingcancermetastasizedtobone AT panyihuai designofpolyasparticacidpeptidepolyethyleneglycolpolyecaprolactonenanoparticlesasacarrierofhydrophobicdrugstargetingcancermetastasizedtobone |